EHS
EHS

Tirbanibulin for Actinic Keratosis: Insights into the Mechanism of Action


Brian Berman has received grants or research funding from Biofrontera, LEO Pharma, and Sirnaomics. He is a consultant to Aiviva, Almirall, Biofrontera, Castle Biosciences, Inc., LEO Pharma, Mediwound, PHD Biosciences, Sirnaomics, and Sun Pharma. He has attended speakers’ bureaus for Almirall, and Sun Pharma, and served on advisory boards for Almirall, Biofrontera, Castle Biosciences, Inc., LEO Pharma, and Sun Pharma. Todd Schlesinger has received grants or research funding from AbbVie, Aclaris Therapeutics, Inc., Akros Pharma, Inc., Allergan, AOBiome Therapeutics, Arcutis Biotherapeutics, Astellas Pharma US, Inc., Bioderma Laboratories, Biofrontera, BioPharmX, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Inc., Celgene, ChemoCentryx, Coherus BioSciences, Corrona, Dermavant, Dermira, Inc., DT Collagen & DT Pharmacy, Eli Lilly & Co., Almirall, Galderma, Genentech, Inc., Janssen/Centocor Ortho Biotech, Inc., Kinex, Kiniksa Pharmaceuticals, LEO Pharma, Merz Pharma, Novartis, Pfizer, Inc., Regeneron Pharmaceuticals, Sanofi Genzyme, SiSaf, Ltd., Tetraderm Group, LLC, and Trevi Therapeutics. He is a consultant to AbbVie, Aclaris Therapeutics, Inc., Allergan, Almirall, Biofrontera, Bristol-Myers Squibb, Castle Biosciences, Inc., Eli Lilly & Co., EPI Health, Evolus, Foundation for Research and Education in Dermatology, Galderma, LEO Pharma, MED Learning Group CME Program, Merz Pharma, MJH Associates ONCLive SCC Filming, Novartis, Ortho Dermatologics, Pfizer, Inc., Prolacta Bioscience, Regeneron Pharmaceuticals, SiSaf, Ltd., Sun Pharma, Suneva Medical, Inc., and UCB Pharma. He has attended speakers’ bureaus for Aclaris Therapeutics, Inc., Almirall, Dermira, Inc., DUSA Pharmaceuticals, EPI Health, Regeneron Pharmaceuticals, Sanofi-Aventis, Sanofi Genzyme, Sun Pharma, and Suneva Medical, Inc.; and served on advisory boards for Allergan, Almirall, Bioderma Laboratories, Biofrontera, Celgene, Greenway Therapeutix, Remedly, and Suneva Medical, Inc. He is also co-chair committee and/or performance measurement, corporate relations committee member for American Academy of Dermatology Actinic Keratosis Guideline and Actinic Keratosis Performance Measurement Work Group. Eggert Stockfleth has received grants or research funding from Almirall, Pierre Fabre, Aresus and Dr Pfleger. Ayman Grada is the Former Head of R&D and Medical Affairs at Almirall (US). The authors report no other conflicts of interest in this work.



Source link

EHS
Back to top button